TGFB1 and lymphoma: On the other hand, inhibiting Nrf2 signaling decreases phase II antioxidant enzymes and p53 levels, while increasing inflammatory signals, such as TGF-β, and altering iNOS and COX2 regulation in lymphoma-bearing mice [101].